Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc (SMTI) specializes in advanced collagen-based solutions for surgical and chronic wound care, serving healthcare providers through clinically validated technologies. This hub provides investors and medical professionals with centralized access to official corporate developments.
Key Resources: Track FDA clearances for medical devices, quarterly earnings reports detailing commercialization progress, and strategic partnership announcements with healthcare distributors. All content is sourced directly from company filings and verified press releases.
Content Types Include: Product launch details for wound care innovations, financial performance updates, clinical study outcomes, and executive leadership changes. Materials are organized chronologically for historical analysis and trend identification.
Staying Informed: Bookmark this page or check regularly for unedited primary source materials about SMTI's market position in medical technology. Cross-reference with regulatory databases for complete context on product approvals.
Sanara MedTech (NASDAQ: SMTI), a medical technology company focused on surgical, chronic wound and skincare markets, has scheduled its Q3 2024 earnings release for November 12, 2024. The company will host a conference call on November 13, 2024, at 9:00 a.m. Eastern Time. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 373459) or webcast through the company's website. A replay will be available through November 27, 2024.
Sanara MedTech Inc. (NASDAQ: SMTI) and InfuSystem Holdings, Inc. have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, , along with a minority investment. The deal involves:
1. SI Healthcare Technologies, a 50/50 joint venture between Sanara and InfuSystem, becoming the exclusive U.S. distributor of ChemoMouthpiece's kits.
2. Sanara investing $5 million for a 6.6% ownership in ChemoMouthpiece.
3. Distribution of a 510(k) cleared cryotherapy device to reduce oral mucositis in chemotherapy patients.
4. A market opportunity estimated at over $600 million, targeting 500,000 - 1,000,000 annual patients.
5. Potential for cost reductions in oncology treatment centers and improved patient quality of life.
Sanara MedTech Inc. (NASDAQ: SMTI) reported its Q2 2024 results, marking its eleventh consecutive record revenue quarter. The company achieved $20.2 million in sales, a 28% increase from Q2 2023. Despite this growth, Sanara reported a net loss of $3.5 million, compared to a $1.9 million loss in Q2 2023. The increased loss was primarily due to higher SG&A costs, executive separation expenses, and acquisition costs.
Positive developments include Adjusted EBITDA of $0.6 million, improved from -$0.3 million in Q2 2023, and expanded market presence with products sold in over 1,100 facilities across 34 states. Sanara also secured a $55 million non-dilutive term loan to support growth initiatives and made key executive appointments to strengthen its management team.
Sanara MedTech Inc. (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies for surgical, chronic wound, and skincare markets, has announced the dates for its second quarter 2024 earnings release and conference call. The company will issue its earnings release on Monday, August 12, 2024, followed by a conference call on Tuesday, August 13, 2024, at 9:00 a.m. Eastern Time.
Investors can access the conference call via a toll-free number (888-506-0062 for domestic callers, 973-528-0011 for international callers) using the access code 984768. A telephonic replay will be available until August 27, 2024. Additionally, a live webcast of the call will be accessible on the company's website under the Investor Relations section, with a one-year online replay available after the broadcast.
Sanara MedTech Inc. announced its first quarter 2024 results, showcasing a tenth consecutive record revenue quarter with $18.5 million in sales. The company appointed new executive members, entered a $55.0 million non-dilutive term loan agreement, and saw its former CEO resign. Sanara also focused on increasing product usage, resulting in a 19% revenue increase. However, the company reported a net loss of $1.8 million for the quarter, primarily due to increased SG&A costs.
Sanara MedTech Inc., a medical technology company, announced the details for the release of its first quarter earnings for the period ending March 31, 2024. The company will issue its earnings release on May 13, 2024, and host a conference call on May 14, 2024, at 9:00 a.m. Eastern Time. Investors can access the call via phone or webcast.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
